Clinical Trial Update: Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed pioglitazone for major depressive disorder in patients with metabolic syndrome; the study completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Metabolic Syndrome

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Joseph Calabrese, MD | Conditions: Depressive Disorder, Major, Metabolic Syndrome X | Phase 2 | Status: COMPLETED | Results posted: 2014-10-17